Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lyrica launch

Executive Summary

Pfizer's Neurontin follow-on Lyrica is now available in pharmacies, the drug maker announces Sept. 21. Availability of pregabalin comes nine months after FDA's initial approval and almost a year after the launch of Neurontin (gabapentin) generics. FDA approved Lyrica in December for treatment of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia; the product added an indication in June for adjunctive treatment of partial onset seizures in adults (1"The Pink Sheet" June 20, 2005, p. 25). The Schedule V controlled substance completed Drug Enforcement Administration scheduling in July, but its launch was stalled pending production of packaging including the controlled substance information, according to Pfizer....
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel